Tristar Wellness (TWSI) Fair Value & Analysis

Healthcare · US · Market cap $132K

Below-average quality, and screening another 15% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($0.0017). The favourable scenario is already priced in.
• Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range $0.0001 – $0.2890 · the $0.0020 price screens above the $0.0017 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Tristar Wellness (TWSI) currently trades at $0.0020, while our model-based Fair Value estimate is $0.0017, implying the stock looks roughly 15.0% overvalued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at $4.0M. Revenue declined 49.9% year over year. Net debt stands at $9.3M. Fundamentals as of Aug 13, 2026

For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -15%, TWSI screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models ($0.0020) versus DCF Models ($0.0020). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Tristar Wellness Solutions Inc. engages in the development, marketing, and sale of wound care products. The company offers skincare and other products under the Beaute de Maman name for pregnant and nursing women; bleeding and wound management products for surgical, health care, consumer, and military markets; and develops and markets Delivery Devise with …

Full company description

Tristar Wellness Solutions Inc. engages in the development, marketing, and sale of wound care products. The company offers skincare and other products under the Beaute de Maman name for pregnant and nursing women; bleeding and wound management products for surgical, health care, consumer, and military markets; and develops and markets Delivery Devise with Invertible Diaphragm, which is a medical applicator for delivering medicants and internal devices within the body without producing injury or damage. It also develops over-the-counter itch suppression products; and develops, manufactures, and markets wound care and infection control medical devices. The company was formerly known as BioPack Environmental Solutions, Inc. and changed its name to Tristar Wellness Solutions Inc. in January 2013. Tristar Wellness Solutions Inc. was incorporated in 2000 and is based in Portland, Oregon. On January 15, 2016, TriStar Wellness Solutions, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Oregon.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2010 – FY2024 · reported fiscal years

Tristar Wellness reported revenue of $5.5M in FY2014 versus $921K in FY2010, a compound +56.7%/yr. Reported net income was −$18.4K in FY2024.

TWSI screens 15% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.